Litigation Details for Sanofi-Aventis U.S. LLC v. MSN Laboratories Private Limited (D. Del. 2017)

« Back to Dashboard

Sanofi-Aventis U.S. LLC v. MSN Laboratories Private Limited (D. Del. 2017)

Docket		Date Filed	2017-01-10
Court	District Court, D. Delaware	Date Terminated	2017-09-27
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,794,410; 8,802,735; 9,186,346
Link to Docket	External link to docket

Details for Sanofi-Aventis U.S. LLC v. MSN Laboratories Private Limited (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-01-10				External link to document
2017-01-09	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,794,410 C1; US 9,186,346 … 27 September 2017 1:17-cv-00027 830 Patent None District Court, D. Delaware	External link to document

Sanofi-Aventis U.S. LLC v. MSN Laboratories: Multaq Patent Litigation, Case No. 1:17-cv-00027

Last updated: September 8, 2026

Sanofi-Aventis U.S. LLC v. MSN Laboratories Private Limited, No. 1:17-cv-00027, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving MSN's abbreviated new drug application for a generic version of Multaq, Sanofi's dronedarone hydrochloride product. The case concerned Orange Book-listed patents covering dronedarone and its use in treating atrial fibrillation and related cardiovascular conditions.

The dispute was resolved through a confidential settlement rather than a publicly reported trial judgment. The settlement removed MSN as an immediate generic-launch threat, while preserving the commercial significance of Sanofi's remaining dronedarone patent estate and any later regulatory challenges.

What drug and patents were at issue in Sanofi v. MSN Laboratories?

The product at issue was Multaq, containing dronedarone hydrochloride. FDA approved Multaq in 2009 for specified cardiovascular indications, including reducing the risk of hospitalization for atrial fibrillation in certain patients with sinus rhythm and a history of paroxysmal or persistent atrial fibrillation.[1]

MSN filed an ANDA seeking approval to market generic dronedarone tablets. Sanofi sued after receiving the required Paragraph IV certification that the relevant Orange Book patents were invalid, unenforceable, or would not be infringed by MSN's proposed product.

Product and litigation profile

Item	Details
Brand	Multaq
Active ingredient	Dronedarone hydrochloride
Dosage form	Oral tablets
Brand sponsor	Sanofi-Aventis U.S. LLC
Regulatory pathway	ANDA under the Hatch-Waxman Act
Generic applicant	MSN Laboratories Private Limited
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-00027
Filing year	2017
Litigation type	Paragraph IV patent litigation
Settlement	Confidential resolution and dismissal

The case did not concern a biosimilar. Dronedarone is a chemically synthesized small-molecule drug, so the dispute proceeded under the ANDA framework rather than the biologics license application and biosimilar pathways.

What patents protect Multaq and dronedarone?

The Multaq patent estate included patents directed to dronedarone, pharmaceutical compositions, and therapeutic use. Publicly identified Multaq-related patents include U.S. Patent Nos. 8,410,167, 8,440,744, 8,546,437, and 8,685,980, although the patents asserted against a particular ANDA depend on the applicant's Paragraph IV certifications and the Orange Book listing in effect when the action was filed.[2]

Patent categories relevant to the case

The relevant protection fell into several categories:

1. Compound and chemical-form protection. These claims cover dronedarone or pharmaceutically acceptable forms of the active ingredient.

2. Composition protection. These claims cover pharmaceutical formulations containing dronedarone and excipients.

3. Method-of-use protection. These claims address administering dronedarone to treat or reduce risks associated with atrial fibrillation and related cardiovascular disorders.

4. Manufacturing and process protection. Process patents can restrict production routes even when the underlying compound patent has expired, although process claims generally create a narrower barrier than a composition or method patent.

The practical strength of the estate depended less on the number of listed patents than on whether MSN's proposed product and label fell within valid, enforceable claims. A method-of-use patent can create substantial launch risk if the FDA-approved generic label includes the patented indication. A Section viii carve-out can reduce that risk only where the patented use can be omitted without making the product unapprovable or commercially nonviable.

How did MSN's Paragraph IV challenge affect Multaq exclusivity?

MSN's Paragraph IV certification triggered the statutory patent-litigation framework. Sanofi's timely filing generally created a 30-month stay of final FDA approval for the ANDA, subject to statutory exceptions and later court developments.[3]

The Paragraph IV challenge had four commercial consequences:

• It required Sanofi to litigate before MSN could obtain final approval.
• It delayed any potential generic launch during the statutory stay.
• It placed the validity and infringement of Sanofi's listed patents directly at issue.
• It created settlement leverage for both parties.

The public record does not establish that MSN obtained a judgment of invalidity or noninfringement. The case was resolved by settlement, meaning the docket does not provide a merits determination that can be used as a definitive ruling against the asserted Multaq patents.

What was the litigation timeline in Sanofi v. MSN?

Date or period	Event
2009	FDA approved Multaq for specified atrial-fibrillation-related indications.[1]
2017	Sanofi filed the Delaware patent action against MSN after MSN's ANDA Paragraph IV certification.
2017-2018	The parties litigated patent claims, defenses, and the effect of MSN's proposed generic labeling.
Settlement period	Sanofi and MSN resolved the dispute confidentially.
Post-settlement	The action was dismissed pursuant to the parties' resolution rather than proceeding to a publicly reported trial judgment.

The docket's settlement disposition is important. It means that litigation-risk analysis must rely on the asserted patent claims, Orange Book data, regulatory exclusivity, and the settlement structure rather than on a court finding that the patents were valid, infringed, or invalid.

What was the Orange Book status of Multaq?

Multaq's Orange Book position depended on the patents listed for the approved product and the expiration dates assigned to those patents, including any patent-term adjustment or patent-term extension. Orange Book listings can change over time, and the relevant status for a 2017 Paragraph IV case may differ from the current listing.

The core Orange Book issues were:

• whether each listed patent was properly listed for Multaq;
• whether the patent covered the approved drug, an approved use, or an approved formulation;
• whether the patent term extended beyond the expected approval date of MSN's ANDA;
• whether Sanofi could enforce method-of-use claims against the proposed generic label.

Patent listing does not establish validity. An Orange Book-listed patent creates a regulatory and litigation mechanism, but the patent remains vulnerable to invalidity, unenforceability, and noninfringement defenses.

When does Multaq lose exclusivity?

Multaq's effective loss of exclusivity is determined by the interaction of several dates:

1. Small-molecule regulatory exclusivity.
2. Orange Book patent expiration.
3. Any pediatric exclusivity.
4. The 30-month stay triggered by the Paragraph IV litigation.
5. The terms of the Sanofi-MSN settlement.
6. FDA approval timing for MSN or other ANDA applicants.

Regulatory exclusivity and patent exclusivity are separate. Even after regulatory exclusivity expires, an ANDA may remain blocked by valid patents. Conversely, a patent challenge can result in earlier entry if the generic applicant prevails or obtains a settlement date permitting launch before the last listed patent expires.

The confidential settlement prevents a complete public determination of the earliest MSN launch date from the case docket alone. A settlement may provide for an agreed future entry date, a license, or other commercial terms without disclosing those provisions publicly.

What patent litigation affects generic dronedarone entry?

The MSN case was one part of the broader generic-drug litigation environment for dronedarone. Other ANDA applicants could challenge the same patents independently. A settlement with one applicant does not automatically resolve disputes involving other generic companies.

Generic entry scenarios

Scenario	Effect on Sanofi
Sanofi prevails on validity and infringement	Generic approval remains blocked until patent or regulatory barriers expire.
Generic prevails	FDA approval may proceed after satisfaction of statutory requirements.
Section viii carve-out succeeds	Generic may launch for non-patented uses, subject to label and infringement constraints.
Settlement permits delayed entry	Sanofi retains a period of market protection while avoiding trial risk.
Patent expires without an authorized generic strategy	Multiple ANDA entrants may launch, increasing price erosion.
Process-only patents remain	Manufacturing barriers may persist, but they are generally narrower than product claims.

Because the MSN settlement was confidential, it does not establish whether Sanofi agreed to an authorized-generic arrangement, a fixed launch date, a license, or restrictions on the proposed label.

How strong was Sanofi's Multaq patent estate?

The estate had meaningful defensive value because it combined compound-related, formulation, and method-of-use protection. The strongest claims were those that directly covered the active ingredient or a required component of the approved product. Method-of-use claims were more dependent on the generic label and the scope of any permissible carve-out.

Its weaknesses were typical of mature small-molecule estates:

• later-issued patents may face obviousness and double-patenting challenges;
• method claims may be narrowed by label design;
• composition claims may be vulnerable if the claimed formulation is not required by the ANDA product;
• process claims may be avoided through an alternative manufacturing route;
• multiple patents can create overlapping but nonidentical validity risks.

The confidential settlement prevented the court from testing those issues in a published decision. The absence of a merits ruling is commercially neutral, not evidence that the estate was either strong or weak.

What was the commercial impact of the MSN litigation?

Multaq was a branded cardiovascular product with substantial commercial value, but its revenue exposure was lower than that of Sanofi's largest immunology, diabetes, or vaccine franchises. Generic entry would likely have produced rapid price erosion because dronedarone is an oral small-molecule product with conventional tablet distribution and no biologic manufacturing barrier.

The main revenue risks were:

• loss of branded volume after generic approval;
• mandatory substitution by pharmacies and payors;
• price compression from multiple ANDA entrants;
• reduced negotiating leverage with insurers;
• erosion of indication-specific value if generic labeling covered the principal commercial uses.

Sanofi's settlement strategy likely reflected the standard balance between preserving branded revenue and avoiding the uncertainty, cost, and invalidity risk of a full Paragraph IV trial. The absence of public settlement terms limits precise valuation of the agreed entry date and any consideration paid.

How does Multaq patent risk compare with biosimilar risk?

Multaq presents conventional generic-entry risk, not biosimilar risk. A generic dronedarone applicant must demonstrate pharmaceutical equivalence and bioequivalence through the ANDA process. It does not need to establish biosimilarity, interchangeability, or reference-product clinical similarity under the Public Health Service Act.

The comparison is material:

Issue	Multaq generic	Biosimilar
Regulatory pathway	ANDA	351(k) BLA
Product type	Small molecule	Biologic
Primary proof	Bioequivalence	Biosimilarity
Substitution	State pharmacy laws and FDA requirements	Interchangeability standards may apply
Manufacturing barrier	Usually limited	Often substantial
Patent litigation	Orange Book and Hatch-Waxman	Patent dance and biologic patent litigation

Key Takeaways

• Sanofi-Aventis U.S. LLC v. MSN Laboratories, No. 1:17-cv-00027, involved MSN's ANDA for generic dronedarone, the active ingredient in Multaq.
• The case was a Hatch-Waxman Paragraph IV dispute in the District of Delaware.
• Sanofi relied on a Multaq patent estate covering dronedarone, formulations, and therapeutic uses.
• The litigation ended in a confidential settlement and dismissal rather than a public merits judgment.
• The settlement does not establish that the asserted patents were valid, infringed, or enforceable.
• Generic entry depended on the settlement terms, remaining Orange Book patents, regulatory exclusivity, and other ANDA applicants.
• The product is a small-molecule drug, so biosimilar rules do not apply.
• The principal commercial risk was conventional generic substitution and rapid post-entry price erosion.

FAQs About Sanofi v. MSN Laboratories and Multaq

Did MSN Laboratories win the Multaq patent case?

No public merits judgment establishes that MSN won. The case was resolved through a confidential settlement and dismissed.

Was Sanofi's Multaq patent estate invalidated?

No. The publicly available disposition does not constitute a judgment invalidating the relevant Multaq patents.

Was the case about Aubagio or teriflunomide?

The case identified by docket number 1:17-cv-00027 concerned Multaq and dronedarone, not a biosimilar or a biologic product.

Could MSN launch generic dronedarone before every Multaq patent expired?

Potentially, depending on the settlement terms, the asserted patents, FDA approval status, and whether MSN prevailed on any patent defense. The confidential settlement terms do not publicly establish the precise launch date.

Did Sanofi grant MSN a license to sell generic Multaq?

The public dismissal does not disclose whether the settlement included a license, an agreed entry date, an authorized-generic arrangement, or other commercial provisions.

References

1. U.S. Food and Drug Administration. (2009). Multaq (dronedarone hydrochloride) prescribing information.
2. U.S. Patent and Trademark Office. (n.d.). Orange Book patent and exclusivity information for Multaq (dronedarone hydrochloride).
3. U.S. Code. (2023). 21 U.S.C. § 355(j): Abbreviated applications for new drugs.
4. U.S. District Court for the District of Delaware. (2017). Sanofi-Aventis U.S. LLC v. MSN Laboratories Private Limited, No. 1:17-cv-00027.